medwireNews

Oral insulin 338, a long-acting basal insulin analog, provides similar glycemic control to that achieved with insulin glargine among insulin-naive patients with type 2 diabetes, phase II study data show.

Tumor mutational burden could be a cross-tumor predictive biomarker of immunotherapy, say US researchers who found an association between mutational load and survival across a wide range of malignancies treated with immune checkpoint inhibitors.

Poor glycemic control is associated with an increased risk for low-trauma fracture in people with type 1, but not type 2, diabetes, study findings indicate.

Second-line treatment with vascular endothelial growth factor receptor–tyrosine kinase inhibitors after failure of nivolumab plus ipilimumab continues to benefit patients with metastatic renal cell carcinoma, report researchers.

A dose-reduction strategy may be feasible for ankylosing spondylitis patients in sustained clinical remission with tumor necrosis factor inhibitor treatment, findings from the open-label REDES-TNF trial suggest.

Adjuvant treatment with sunitinib may be associated with an increased mortality risk for older female patients with renal cell carcinoma, suggests a post-hoc analysis of the ASSURE trial that compared sunitinib and sorafenib with placebo.